Balentine LLC Biomarin Pharmaceutical Inc Transaction History

Balentine LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	SELL	$80.93 - $108.63 $17,157 - $23,029	-212 Reduced 8.77%	2,206 $228,000
Q3 2022 Oct 26, 2022	SELL	$82.16 - $96.94 $24,319 - $28,694	-296 Reduced 10.91%	2,418 $205,000
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $193,996 - $235,710	2,714 New	2,714 $225,000
Q3 2020 Nov 02, 2020	SELL	$71.87 - $131.03 $2,012 - $3,668	-28 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $19,728 - $30,806	-248 Reduced 89.86%	28 $3,000
Q1 2020 May 18, 2020	BUY	$71.37 - $96.85 $19,698 - $26,730	276 New	276 $23,000
Q4 2019 Sep 02, 2020	SELL	$64.27 - $86.37 $2,377 - $3,195	-37 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$67.4 - $85.11 $2,493 - $3,149	37 New	37 $2,000
Q1 2018 May 16, 2018	SELL	$77.67 - $92.63 $3,262 - $3,890	-42 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $3,634 - $4,280	-45 Reduced 51.72%	42 $4,000
Q3 2017 Nov 15, 2017	BUY	$80.6 - $94.95 $7,012 - $8,260	87	87 $8,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

Stay updated on Balentine LLC with notifications on news.